Stock On Watch: Why Julian Baker And Felix Baker’s Baker Bros. Advisors Lp Reported Big Seattle Genetics Inc Wa Position?

Stock On Watch: Why Julian Baker And Felix Baker's Baker Bros. Advisors Lp Reported Big Seattle Genetics Inc Wa Position?

The New Julian Baker And Felix Baker’s Baker Bros. Advisors Lp Holding in Seattle Genetics Inc Wa

Baker Bros. Advisors Lp filed with the SEC SC 13D/A form for Seattle Genetics Inc Wa. The form can be accessed here: 000114420416132847. As reported in Julian Baker And Felix Baker’s Baker Bros. Advisors Lp’s form, the filler as of late owns 32.4% or 45,959,548 shares of the Health Care–company.

Seattle Genetics Inc Wa stake is a new one for the for the hedge fund and it was filed because of activity on November 8, 2016. We feel this shows Julian Baker And Felix Baker’s Baker Bros. Advisors Lp’s positive view for the stock. For a hedge fund managing $8.20 billion in assets and having 25+ active experts, we at Financialmagazine have no doubt the buy is a bullish signal.

The hedge fund is active investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Julian Baker And Felix Baker’s Baker Bros. Advisors Lp’s US equities portfolio is in this sector.

Seattle Genetics Inc Wa Institutional Sentiment

Latest Security and Exchange filings show 206 investors own Seattle Genetics Inc Wa. The institutional ownership in Q3 2015 is very high, at 94.73% of the outstanding shares. This is increased by 7823346 the total institutional shares. 134092183 were the shares owned by these institutional investors. In total 29 funds opened new Seattle Genetics Inc Wa stakes, 84 increased stakes. There were 27 that closed positions and 65 reduced them.

4 managers had the stock in their top Ten. Notable investors are: Baker Bros. Advisors Lp, Blue Jay Capital Management Llc, Lagoda Investment Management L.P., Redmile Group Llc, Wasatch Advisors Inc, Opus Point Partners Management Llc..

Emory University is an institutional investor bullish on Seattle Genetics Inc Wa, owning 69008 shares as of Q3 2015 for 6.89% of its portfolio. Wasatch Advisors Inc owns 2960284 shares or 1.53% of its portfolio. CA Redmile Group Llc have 9.90% of their stock portfolio for 1390173 shares. Further, Lagoda Investment Management Lp reported stake worth 7.17% of its US stock portfolio. The NY Baker Bros Advisors Lp owns 36029746 shares. Seattle Genetics Inc Wa is 12.84% of the manager’s US portfolio.

Business Profile

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company’s pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer.

SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.

Insitutional Activity: The institutional sentiment increased to 0.91 in Q2 2016. Its up 0.17, from 0.74 in 2016Q1. The ratio improved, as 12 funds sold all Seattle Genetics, Inc. shares owned while 75 reduced positions. 34 funds bought stakes while 45 increased positions. They now own 136.24 million shares or 2.59% less from 139.87 million shares in 2016Q1.

Assetmark Incorporated accumulated 193 shares or 0% of the stock. Zweig has 0.19% invested in the company for 46,250 shares. Canada Pension Plan Inv Board reported 175,600 shares or 0.03% of all its holdings. Mitsubishi Ufj And Banking has 0.08% invested in the company for 888,429 shares. Blackrock accumulated 13,544 shares or 0% of the stock. Paloma Prtnrs Management Co holds 22,133 shares or 0.01% of its portfolio. Berson Corrado Inv Advsr owns 57,305 shares or 1.5% of their US portfolio. Pinnacle Assoc Ltd reported 1.19M shares or 1.03% of all its holdings. Moreover, Jpmorgan Chase & Co has 0% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 3,595 shares. Ameriprise has 0% invested in the company for 49,820 shares. Soros Fund Ltd Liability Com holds 0.01% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 14,700 shares. Essex Co Ltd holds 0.07% or 9,877 shares in its portfolio. Bnp Paribas Arbitrage Sa last reported 0% of its portfolio in the stock. Bancorp Of Montreal Can reported 1,050 shares or 0% of all its holdings. Manning & Napier Advisors Lc holds 0.06% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 228,321 shares.

Insider Transactions: Since May 17, 2016, the stock had 3 buys, and 22 selling transactions for $88.60 million net activity. Another trade for 11,660 shares valued at $550,212 was made by SIEGALL CLAY B on Monday, August 8. Shares for $141,617 were sold by Cline Darren S. On Wednesday, September 14 the insider DOBMEIER ERIC sold $1.24M. BAKER FELIX also bought $20.05M worth of Seattle Genetics, Inc. (NASDAQ:SGEN) shares. $185,943 worth of shares were sold by SIMPSON TODD E on Monday, August 22. HIMES VAUGHN B had sold 3,991 shares worth $185,943 on Monday, August 22. DRACHMAN JONATHAN G sold 3,991 shares worth $185,943.

The stock increased 16.41% or $9.75 during the last trading session, hitting $69.17. About 3.58 million shares traded hands or 247.57% up from the average. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 61.86% since April 7, 2016 and is uptrending. It has outperformed by 57.08% the S&P500.

Seattle Genetics, Inc. is a biotechnology firm focused on the development and commercialization of therapies for the treatment of cancer. The company has a market cap of $9.74 billion. The Company’s product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate , comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). It currently has negative earnings. The Company’s pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

Out of 8 analysts covering Seattle Genetics (NASDAQ:SGEN), 5 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 63% are positive. $62 is the highest target while $51 is the lowest. The $57 average target is -17.59% below today’s ($69.17) stock price. Seattle Genetics has been the topic of 14 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The company was maintained on Friday, July 31 by RBC Capital Markets. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Outperform” rating given on Thursday, January 21 by Credit Suisse. RBC Capital Markets maintained it with “Outperform” rating and $62 target price in Monday, October 10 report. The rating was downgraded by Cantor Fitzgerald to “Hold” on Wednesday, July 27. On Thursday, February 4 the stock rating was initiated by Barclays Capital with “Overweight”. RBC Capital Markets maintained the stock with “Outperform” rating in Monday, September 14 report. Piper Jaffray upgraded the shares of SGEN in a report on Friday, October 30 to “Neutral” rating. The stock has “Sell” rating given by Goldman Sachs on Wednesday, November 18. On Tuesday, August 25 the stock rating was maintained by William Blair with “Buy”. The firm earned “Overweight” rating on Wednesday, July 27 by Barclays Capital.

More news for Seattle Genetics, Inc. (NASDAQ:SGEN) were recently published by: Fool.com, which released: “5 Years After Adcetris Approval, Seattle Genetics, Inc. Still Focused on Pipeline” on October 31, 2016. Businesswire.com‘s article titled: “Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical …” and published on November 08, 2016 is yet another important article.

According to Zacks Investment Research, “Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company’s lead product, ADCETRIS® (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available for two indications in more than 45 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME and ASG-15ME.”

SGEN Company Profile

Seattle Genetics, Inc., incorporated on July 15, 1997, is a biotechnology firm focused on the development and commercialization of therapies for the treatment of cancer. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company’s pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. It also has multiple preclinical and research-stage programs that employ its technologies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment